Announcement of the European Congress of Cardiology

From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France). It is expected to attend about 32,000 medicals from 150 countries who will be able to attend 500 scientific sessions with leading experts.

At the Congress, 5 new clinical guidelines will be presented and discussed:

• Recommendations for diabetes, prediabetes and cardiovascular disease

• Recommendations for pulmonary embolism

• Recommendations for supraventricular tachycardia

• Recommendations for chronic coronary syndromes

• Recommendations for dyslipidemia

With particular interest, the first presentation of 25 recently completed randomized clinical trials selected for 6 traditional HOT LINE sessions is expected.

Published press releases allow us to expect research results as the most striking events:

 THEMIS - improvement of clinical outcomes in patients with diabetes mellitus and stable coronary heart disease when ticagrelor is added to the treatment regimen.

DAPA-HF - reduction of the risk of death or hospitalization due to decompensation in patients with chronic heart failure and a reduced left ventricular ejection fraction when dapagliflozin is added to therapy. It is important that a positive effect was achieved not only in patients with diabetes mellitus, but also without diabetes.

COMPLETE - improved outcomes in patients with myocardial infarction with ST segment elevations as a result of complete percutaneous coronary revascularization.

PARAGON-HF - sacubitrile / valsartan, compared with valsartan, did not significantly reduce the total frequency of death from cardiovascular disease and hospitalization due to decompensation in patients with chronic heart failure and a preserved ejection fraction of the left ventricle. However, there has been a definite clinical benefit from sacubitrile / valsartan therapy, which will be reported on September 1.

Scientific news

  • In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.
  • Prenatal Exercise Cuts Common Pregnancy Complications Moderate-intensity physical activity during pregnancy is known to be safe for the mother and foetus, but does it reduce the risk for medical complications? A new up-to-date review summarises the data, including seven meta-analyses, which establishes that prenatal exercise prevents hypertension disorders in pregnancy (HDP), including gestational diabetes mellitus (GDM). These are the most common medical complications of pregnancy, affecting up to 15% of pregnant women.
  • Heart Failure, Not Stroke, Most Common Complication of A-Fib The lifetime risk of atrial fibrillation (AF) increased from 2000 to 2022 from one in four to one in three, a Danish population-based study of temporal trends found.
  • Incremental value of machine learning for risk prediction in tetralogy of Fallot Machine learning (ML) can facilitate prediction of major adverse cardiovascular events (MACEs) in repaired tetralogy of Fallot (rTOF). We sought to determine the incremental value of ML above expert clinical judgement for risk prediction in rTOF.
  • Can Treating Depression Mitigate CVD Risk? Depression is linked to a significantly increased risk for cardiovascular disease (CVD), particularly in women, new data from a large retrospective cohort study show. Researchers suggest that screening and treating patients for depression may lead to a decreased incidence of CVD.

Partners

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru